Combined [18F]-FDG PET-MRI in Diagnostics and Surveillance of Small Bowel Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-01

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with suspected small bowel Crohn's disease (CD) are assessed with PET-MRE using 18-fluorodeoxyglucose (\[18F\]-FDG) tracer. Patients are recruited from the outpatient clinic of gastroenterology in Turku University Hospital. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study. This is an observational single-center imaging study.

35 patients with high clinical suspicion of active small bowel CD will be enrolled to study. After the diagnostic \[18F\]-FDG-PET-MRE, patients will undergo small bowel capsule endoscopy (SBCE) if no strictures are seen in PET-MRE. \[18F\]-FDG-PET-MRE will be repeated in 3 months after medical therapy for CD has been started. Medical therapy will be started by clinicians blinded from PET-data but have access to MRE-data and all other diagnostic measures. Adequate medication is chosen by clinicians not participating in the study and thus enrollment does not affect the choice of medical therapy for patients participating in this study. \[18F\]-FDG-PET-MRE and clinical assessment of disease activity will be performed within 1 month of recruitment. Follow up-visits will be arranged in the outpatient clinic of gastroenterology in Turku University Hospital.

The aim is to investigate whether \[18F\]-FDG-PET-MRE can be used in diagnostics and follow-up of small bowel CD and to compare its performance to MRE.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of VAP-1 Expression and Tissue Blood Flow by PET-MRI in Patients With Crohn's Disease

NCT06555042

Crohn Disease Inflammatory Bowel Diseases Crohn Disease of Small Intestine +3 more

RECRUITING

Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study

NCT02364973

IBD

COMPLETED

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

NCT06252493

Crohn Disease

RECRUITING

Development of Inflammation and Fibrosis Index, Combining MRI and PET 18F-FDG, in Patient's With Crohn's Disease

NCT04467580

Crohn Disease

UNKNOWN NA

Early MRI Prediction of Crohns

NCT03340519

Crohn Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diagnostics and follow up of small bowel CD can be difficult, large parts of small bowel can't be assessed by conventional endoscopy. MRE can detect transmural lesions, but sensitivity is limited with luminal disease. SBCE can detect even small lesions, but specificity is low. More accurate tools for diagnostics are hence needed. Our aim is to is to show that \[18F\]-FDG-PET-MRE can be used in diagnostics and disease activity monitoring of small bowel CD

Volunteer patients with clinically suspected small bowel CD (i.e. ileitis in colonoscopy, diarrhea, anemia and elevated fecal calprotectin or suspected CD in cross sectional imaging) are recruited from the outpatient clinic of gastroenterology in Turku University Hospital. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study. All patients have previously been in ileocolonoscopy.

After screening, the patients have routine blood samples taken. A complete blood count (CBC), C-reactive protein (CRP), creatinine, alanine aminotransferase (ALAT), alkaline phosphatase (AFOS) and albumin will be analyzed from each patient's blood sample and fecal calprotectin analyzed from stool. Patients are then assessed with PET-MRE using 18-fluorodeoxyglucose (\[18F\]-FDG) tracer. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study.

Patients fast for six hours prior to PET-MRE study. Oral mannitol is used as enteral contrast. Venous catheters will be placed at both antecubital veins for injection of \[18F\]-FDG and gadolinium contrast agent for MRE-sequences. Patients will lie prone for approximately 1.5h during the PET-MRE imaging. Prior to imaging, fasting glucose is measured from venous blood. During the imaging, FDG -activity will be measured from venous blood. The uptake of FDG in small bowel will be measured from the images obtained from segments with inflammation and healthy-looking segments for comparison.

If no strictures are present in the PET-MRE, the patients will go through SBCE to confirm the diagnosis of small bowel CD. The patients are arranged a visit to clinician in the outpatient clinic of gastroentereology in Turku University Hospital. The clinicians have access to MRE-data, endoscopy and SBCE-data and laboratory data, but are blinded from PET-results to avoid bias. The clinicians choose adequate treatment for each patient individually following general guidelines (such as ECCO) of treatment of small bowel CD. The patients diagnosed with small bowel CD will undergo a repeated PET-MRE following the same protocol as the first diagnostic PET-MRE to assess response to therapy. After the follow-up PET-MRE, patients medical history including laboratory and medication data will be followed and gathered for 12 months.

Primary outcome is to show that standardized uptake values (SUV) measured in \[18F\]-FDG-PET-MRE are higher in patients with CD than in patients not diagnosed with CD.

Secondary outcome is to show that starting effective medical therapy to small bowel CD decreases SUV in small bowel segments with CD inflammation. Secondary aim is also to investigate whether changes in SUV can predict long term disease outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Bowel Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study subjects

Patients with suspected small bowel Crohn's disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinically suspected small bowel CD
* or ileitis in colonoscopy
* or diarrhea or anemia and elevated fecal calprotectin
* or suspected CD in cross sectional imaging)